Gene · 64783
Papers2,224
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
241 to 260 of 2,224
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Crosstalk between m6A modification and alternative splicing during cancer progression. | Clin Transl Med | 2023 | 37850412 | PubTator, text mining | PubMed |
| Molecular subtypes based on N6-methyladenosine RNA methylation demonstrate the heterogeneity of immune and biological functions in pediatric septic shock. | Heliyon | 2023 | 37842565 | PubTator, text mining | PubMed |
| Methylomics and cancer: the current state of methylation profiling and marker development for clinical care. | Cancer Cell Int | 2023 | 37840147 | PubTator, text mining | PubMed |
| METTL3-mediated m6A modification of circRNF220 modulates miR-330-5p/survivin axis to promote osteosarcoma progression. | J Cancer Res Clin Oncol | 2023 | 37838643 | PubTator, text mining | PubMed |
| Whole-exome sequencing reveals mutational profiles of anorectal and gynecological melanoma. | Med Oncol | 2023 | 37831226 | PubTator, text mining | PubMed |
| N6-methyladenosine modification-a key player in viral infection. | Cell Mol Biol Lett | 2023 | 37828480 | PubTator, text mining | PubMed |
| Crosstalk of RNA methylation writers defines tumor microenvironment and alisertib resistance in breast cancer. | Front Endocrinol (Lausanne) | 2023 | 37818090 | PubTator, text mining | PubMed |
| CSTF2 mediated mRNA N6-methyladenosine modification drives pancreatic ductal adenocarcinoma m6A subtypes. | Nat Commun | 2023 | 37816727 | PubTator, text mining | PubMed |
| IGF2BP2 acts as a m6A modification regulator in laryngeal squamous cell carcinoma through facilitating CDK6 mRNA stabilization. | Cell Death Discov | 2023 | 37816718 | PubTator, text mining | PubMed |
| The predictive significance of a 5-m6A RNA methylation regulator signature in colorectal cancer. | Heliyon | 2023 | 37810844 | PubTator, text mining | PubMed |
| Remimazolam relieved the injury of hypoxia/reperfusion treated human embryo liver cell line through the targeting METTL3 mediated m6A modification of P53. | Heliyon | 2023 | 37809663 | PubTator, text mining | PubMed |
| Association between ankylosing spondylitis and m6A methylation. | J Orthop Surg Res | 2023 | 37805597 | PubTator, text mining | PubMed |
| Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. dissect cancer heterogeneity and tailor the treatment. | J Exp Clin Cancer Res | 2023 | 37803464 | PubTator, text mining | PubMed |
| STARD12/14 are diagnostic and prognostic biomarkers of lung adenocarcinoma associated with epigenetic regulation, immune infiltration and ferroptosis. | Int J Med Sci | 2023 | 37790851 | PubTator, text mining | PubMed |
| M6A methylation modification in autoimmune diseases, a promising treatment strategy based on epigenetics. | Arthritis Res Ther | 2023 | 37784134 | PubTator, text mining | PubMed |
| Characteristics of m6A-related LncRNAs in breast cancer as prognostic biomarkers and immunotherapy. | J Cancer | 2023 | 37781080 | PubTator, text mining | PubMed |
| MKL-1 suppresses ferroptosis by activating system Xc- and increasing glutathione synthesis. | Int J Biol Sci | 2023 | 37781038 | PubTator, text mining | PubMed |
| Role of histone lactylation interference RNA m6A modification and immune microenvironment homeostasis in pulmonary arterial hypertension. | Front Cell Dev Biol | 2023 | 37771377 | PubTator, text mining | PubMed |
| N6-methyladenosine (m6A) modification in osteosarcoma: expression, function and interaction with noncoding RNAs - an updated review. | Epigenetics | 2023 | 37766615 | PubTator, text mining | PubMed |
| A New Understanding of Long Non-Coding RNA in Hepatocellular Carcinoma-From m6A Modification to Blood Biomarkers. | Cells | 2023 | 37759495 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/64783/papers?page=13